Letter/Communication
Amantadine for Severe Traumatic Brain Injury
The New England journal of medicine, Vol.366(25), pp.2427-2428
06/21/2012
DOI: 10.1056/NEJMc1204669
PMID: 22716986
Abstract
To the Editor:
In their assessment of the pace of functional recovery in patients with severe traumatic brain injury who received amantadine or placebo, Giacino et al. (March 1 issue)
1
report the rate of change in Disability Rating Scale (DRS) scores in both study groups, but unfortunately, they do not indicate whether their findings were associated with any minimal clinically important difference. This concept has become of increasing importance in the medical literature as clinicians and policymakers seek to verify whether the statistical significance so often shown in clinical trials actually translates into meaningful clinical improvement.
2
,
3
Rather than focusing . . .
Details
- Title: Subtitle
- Amantadine for Severe Traumatic Brain Injury
- Creators
- Brian J Dlouhy - University of Iowa Hospitals and Clinics, Iowa City, IARajesh C Rao - Washington University School of Medicine, St. Louis, MO
- Resource Type
- Letter/Communication
- Publication Details
- The New England journal of medicine, Vol.366(25), pp.2427-2428
- DOI
- 10.1056/NEJMc1204669
- PMID
- 22716986
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Language
- English
- Date published
- 06/21/2012
- Academic Unit
- Iowa Neuroscience Institute; Neurosurgery
- Record Identifier
- 9984071725502771
Metrics
24 Record Views